HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cannabis Industry Taking Legal Action Against EU Regulators Over CBD Novel Food Classification

Executive Summary

The Cannabis Trades Association UK has initiated legal proceedings to challenge the European Commission's recent decision to classify CBD as a novel food. Meanwhile, the UK government has released an official response to the EU's decision. 

You may also be interested in...



European Hemp Players Join Forces To Make Legal CBD Market A Reality

Europe's hemp industry is tired of operating in limbo and wants to secure a fully regulated CBD market as soon a possible. Industry players will pool resources and invest €3.5m to win novel food approval for a number of different CBD products.

CBD Industry Group Commits To Compliance With EU Novel Food Law

Seeking to end the current impasse between regulators and the CBD industry, the Centre For Medicinal Cannabis is launching a quality charter for its members to put their products “on the path to regulatory compliance.” 

European CBD Market Snapshot: UK Leads As Retailers Get On Board With FSA Decision Pending

The UK's cannabidiol market, which according to the Cannabis Trades Association is the largest in Europe, awaits clarification on the legal status of CBD-containing food supplements. Meanwhile, major retailers like Walgreen Boots Alliance are stepping into the space with branded products. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel